Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02639065 · ClinicalTrials.gov registry record · Phase 2
A Study of Durvalumab (MEDI4736) in Esophageal Cancer
A Phase 2 study of Esophageal Cancer, sponsored by Shadia Jalal, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 3
- Study locations
NCT02639065 is a Phase 2 study of Esophageal Cancer that has completed, run by Shadia Jalal, MD. The registered enrollment target is 39 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02639065, a Phase 2 study of Esophageal Cancer, has completed, sponsored by Shadia Jalal, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II, open-label, single arm, single-stage study. A total of 23 evaluable patients will be enrolled. If total number of patients free of disease relapse at 1 year is less than or equal to 15, the drug would not be considered for further study in this setting. After six patients are treated with at least one dose of study drug, they will be observed for a minimum of 60 days. During the 60-day observation period, further accrual will be halted to evaluate "unacceptable toxicities warranting early closure of the trial" defined as: * Any definitive durvalumab-related death. A durvalumab-related death will be continuously monitored throughout the trial and the trial will be suspended for re-evaluation whenever such an event is confirmed. * Any unexpected and previously unreported grade 4 toxicities definitely related to durvalumab.
Conditions Studied
Interventions
- DRUG Durvalumab
Study Locations (3)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- Unversity of Iowa Hospital and Clinics - Iowa City
Michigan
- University of Michigan Health System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-04-27 |
| Est. Completion | 2021-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02639065
The ClinicalTrials.gov registry entry for NCT02639065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Shadia Jalal, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab is the first listed.
NCT02639065 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Iowa, Michigan.
Frequently Asked Questions
What is clinical trial NCT02639065 about?
NCT02639065 is a clinical study titled "A Study of Durvalumab (MEDI4736) in Esophageal Cancer". This is a phase II, open-label, single arm, single-stage study. A total of 23 evaluable patients will be enrolled. If total number of patients free of disease relapse at 1 year is less than or equal to 15, the drug would not be considered for further study in this setting. After six patients are tre...
What is the current status of trial NCT02639065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2016-04-27. Estimated completion is 2021-06-09.
What conditions does trial NCT02639065 study?
This clinical trial studies the following conditions: Esophageal Cancer.
What interventions are being tested in trial NCT02639065?
The interventions under investigation include: Durvalumab (DRUG).
Who is sponsoring clinical trial NCT02639065?
This trial is sponsored by Shadia Jalal, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02639065 being conducted?
This trial has 3 study locations across Indiana, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.